Evidence map›Paper›PMID 23244588›Full record

ArticleCell transplantation2013

BMP2 is superior to BMP4 for promoting human muscle-derived stem cell-mediated bone regeneration in a critical-sized calvarial defect model.

Xueqin Gao, Arvydas Usas, Aiping Lu, Ying Tang, Bing Wang, Chien-Wen Chen, Hongshuai Li, Jessica C Tebbets, James H Cummins, Johnny Huard

Open access · greenAbstract read
In one paragraph

Article in Cell transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Stem Cells and Bone Tissue Engineering.Life (Basel, Switzerland) · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Metabolic Coordination of Pericyte Phenotypes: Therapeutic Implications.Frontiers in cell and developmental biology · 2020
    Review
  12. Article
  13. Hypoxia-inducible factor 1α (HIF-1α) is a major determinant in the enhanced function of muscle-derived progenitors from MRL/MpJ mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  14. Article
  15. Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects.Frontiers in bioengineering and biotechnology · 2018
    Review
  16. Tissue engineering. Part C, Methods · 2017
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xueqin GaoStem Cell Research Center, Growth and Developmental Laboratory, Department of Orthopaedic Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Arvydas Usas
Aiping Lu
Ying Tang
Bing Wang
Chien-Wen Chen
Hongshuai Li
Jessica C Tebbets
James H Cummins
Johnny Huard
University of Pittsburgh · US

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
Muscle Based Tissue Engineering to Improve Bone HealingR01DE013420 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HUARD, JOHNNY · 2001 to 2010
$3.6M
NIA NIH HHS P30 AG024827NIDCR NIH HHS 5R01-DE13420-09NIDCR NIH HHS R01 DE013420
6 · The paper itself

Abstract

Muscle-derived cells have been successfully isolated using a variety of different methods and have been shown to possess multilineage differentiation capacities, including an ability to differentiate into articular cartilage and bone in vivo; however, the characterization of human muscle-derived stem cells (hMDSCs) and their bone regenerative capacities have not been fully investigated. Genetic modification of these cells may enhance their osteogenic capacity, which could potentially be applied to bone regenerative therapies. We found that hMDSCs, isolated by the preplate technique, consistently expressed the myogenic marker CD56, the pericyte/endothelial cell marker CD146, and the mesenchymal stem cell markers CD73, CD90, CD105, and CD44 but did not express the hematopoietic stem cell marker CD45, and they could undergo osteogenic, chondrogenic, adipogenic, and myogenic differentiation in vitro. In order to investigate the osteoinductive potential of hMDSCs, we constructed a retroviral vector expressing BMP4 and GFP and a lentiviral vector expressing BMP2. The BMP4-expressing hMDSCs were able to undergo osteogenic differentiation in vitro and exhibited enhanced mineralization compared to nontransduced cells; however, when transplanted into a calvarial defect, they failed to regenerate bone. Local administration of BMP4 protein and cell pretreatment with N-acetylcysteine (NAC), which improves cell survival, did not enhance the osteogenic capacity of the retro-BMP4-transduced cells. In contrast, lenti-BMP2-transduced hMDSCs not only exhibited enhanced in vitro osteogenic differentiation but also induced robust bone formation and nearly completely healed a critical-sized calvarial defect in CD-1 nude mice 6 weeks following transplantation. Herovici's staining of the regenerated bone demonstrated that the bone matrix contained a large amount of type I collagen. Our findings indicated that the hMDSCs are likely mesenchymal stem cells of muscle origin and that BMP2 is more efficient than BMP4 in promoting the bone regenerative capacity of the hMDSCs in vivo.

Indexed as

Bone RegenerationAcetylcysteineAdultAged, 80 and overAnimalsBiomarkersBone DiseasesBone Morphogenetic Protein 4Cells, CulturedCell SurvivalDisease Models, AnimalFemaleHumansMaleMiceMice, NudeAcetylcysteineBiomarkersBone Morphogenetic Protein 4

Identifiers

PMID23244588
PMCPMC4361002
OpenAlexW2140374290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.